The National Comprehensive Cancer Network (NCCN) guidelines for NSCLC recommend that biomarker testing should include EGFR mutation, ALK rearrangement, ROS1 rearrangement, NTRK gene fusion, MET amplification, MET exon 14 skipping mutation, RET rearrangement, and HER2 mutation (Table 2). Here, ERBB2 is linked to non-small cell lung carcinoma.